The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
   
a) Discrimination in the work place – increased recognition of migraine.
   
b) There are issues relating to reduced access to treatment for people with mental health issues who experience migraine.
   
c) There are issues relating to the diagnosis of migraine and access to treatment for people from ethnic minorities for whom English is not their first language who experience migraine. For example, questionnaires such as MIDAS require communication with the patient in English.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
   
No change required to the scope.

   The final appraisal determination should address reduced access to diagnosis and treatment with this technology, if recommended, relating to communication difficulties in protected groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Technology Appraisals: Scoping
Equality impact assessment for the proposed Single Technology Appraisal of botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
Issue date: August 2011
<table>
<thead>
<tr>
<th>4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

**Approved by Associate Director (name):** Helen Knight  
**Date:** 12/08/2011